Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CPSI Announces Fourth Quarter and Full Year 2022 Results By: CPSI via Business Wire February 14, 2023 at 16:05 PM EST CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced results for the fourth quarter and year ended December 31, 2022. Highlights include: Fourth quarter 2022 TruBridge revenue cycle management (RCM) revenue grew by 29% compared to fourth quarter 2021, now representing 98% recurring revenue and 55% of CPSI’s total revenue Continued success in both winning new clients and cross-selling RCM solution Full year 2023 revenue guidance between $340 million and $350 million “2022 was an important building year for CPSI as we worked to leverage the well-established organization to drive innovation and growth for the years ahead,” said Chris Fowler, chief executive officer of CPSI. “Our full year results were driven in large part by the success of our TruBridge RCM business as we converted existing customers and focused on adding new, small- and mid-sized hospitals looking to simplify their revenue cycle needs. We also focused on strengthening our customer relationships, which translated to continued stability in our retention rate of over 95%. During the second half of the year, we expanded our leadership team, deepening our expertise and ensuring we are best positioned to execute and seize the growth opportunities ahead of us.” Fourth Quarter 2022 All comparisons are to the quarter ended December 31, 2021, unless otherwise noted. Bookings of $24.7 million compared to $15.6 million Revenue of $83.2 million compared to $74.0 million TruBridge RCM revenue of $45.7 million represented 55% of CPSI’s total revenue, an increase of 29% GAAP net income of $2.5 million and non-GAAP net income of $8.7 million GAAP earnings per diluted share of $0.17 and non-GAAP earnings per diluted share of $0.61 Adjusted EBITDA of $13.2 million compared to $14.3 million Full Year 2022 All comparisons are to the year ended December 31, 2021, unless otherwise noted. Bookings of $89.4 million compared to $70.2 million Revenue of $326.6 million compared to $280.6 million TruBridge RCM revenue of $179.9 million represented 55% of CPSI’s total revenue, an increase of 37% GAAP net income of $15.9 million and non-GAAP net income of $37.0 million GAAP earnings per diluted share of $1.08 and non-GAAP earnings per diluted share of $2.58 Adjusted EBITDA of $55.9 million compared to $52.7 million Net debt of $132.6 million 2023 Outlook For full year 2023, the Company is providing an initial outlook of: Revenue in the range of $340 million to $350 million GAAP net income in the range of $11 million to $15 million Adjusted EBITDA in the range of $59 million to $63 million Conference Call Information CPSI will hold a live webcast to discuss fourth quarter and full year 2022 results today, Tuesday, February 14, 2023, at 4:30 p.m. Eastern time. A 30-day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company’s website, www.cpsi.com. About CPSI CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and other healthcare systems. Founded in 1979, CPSI is the parent of six companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC, iNetXperts, Corp. d/b/a Get Real Health, TruCode LLC, and Healthcare Resource Group, Inc. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive acute care EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of post-acute care EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting and managed IT services, along with its complete RCM solution, for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. TruCode provides medical coding software that enables complete and accurate code assignment for optimal reimbursement. HRG provides specialized RCM solutions for facilities of all sizes. For more information, visit www.cpsi.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; federal, state and local government actions to address and contain the impact of COVID-19 and their impact on us and our hospital clients; operational disruptions and heightened cybersecurity risks due to a significant percentage of our workforce working remotely; saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential inability to properly manage growth in new markets we may enter; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; potential failure to develop new products or enhance current products that keep pace with market demands; failure to develop new technology and products in response to market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; general economic conditions, including changes in the financial and credit markets that may affect the availability and cost of credit to us or our customers; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; lack of employment or non-competition agreement with most of our key personnel; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K. Relative to our dividend policy, the payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our leverage, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release. Computer Programs and Systems, Inc. Condensed Consolidated Statements of Income (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Sales revenues: Revenue cycle $ 45,670 $ 35,491 $ 179,870 $ 131,242 Electronic health record 35,968 35,217 139,823 143,109 Patient engagement 1,586 3,293 6,955 6,278 Total sales revenues 83,224 74,001 326,648 280,629 Costs of sales: Revenue cycle 25,941 17,907 97,010 66,015 Electronic health record 19,069 18,415 71,347 70,664 Patient engagement 1,062 827 3,856 3,068 Total costs of sales 46,072 37,149 172,213 139,747 Gross profit 37,152 36,852 154,435 140,882 Operating expenses: Product development 8,890 7,791 30,926 30,389 Sales and marketing 4,552 6,164 27,131 21,978 General and administrative 14,958 11,700 56,192 50,022 Amortization of acquisition-related intangibles 4,486 3,672 17,403 13,786 Total operating expenses 32,886 29,327 131,652 116,175 Operating income 4,266 7,525 22,783 24,707 Other income (expense): Other income 264 368 1,178 1,529 (Loss) gain on contingent consideration (427 ) - 565 - Loss on extinguishment of debt - - (125 ) - Interest expense (2,276 ) (911 ) (6,320 ) (3,160 ) Total other income (expense) (2,439 ) (543 ) (4,702 ) (1,631 ) Income before taxes 1,827 6,982 18,081 23,076 Provision for income taxes (690 ) 1,581 2,214 4,646 Net income $ 2,517 $ 5,401 $ 15,867 $ 18,430 Net income per common share—basic $ 0.17 $ 0.37 $ 1.08 $ 1.26 Net income per common share—diluted $ 0.17 $ 0.37 $ 1.08 $ 1.26 Weighted average shares outstanding used in per common share computations: Basic 14,210 14,332 14,356 14,290 Diluted 14,210 14,362 14,356 14,318 Computer Programs and Systems, Inc. Condensed Consolidated Balance Sheets (In '000s, except per share data) December 31, 2022 (unaudited) December 31, 2021 (unaudited) Assets Current assets Cash and cash equivalents $ 6,951 $ 11,431 Accounts receivable, net of allowance for doubtful accounts of $2,854 and $1,826, respectively 51,311 34,431 Financing receivables, current portion, net 4,474 6,488 Inventories 784 855 Prepaid income taxes 701 4,599 Prepaid expenses and other 10,338 11,194 Total current assets 74,559 68,998 Property & equipment, net 9,884 11,590 Software development costs, net 27,257 11,644 Operating lease assets 7,567 7,097 Financing receivables, net of current portion 3,312 7,231 Other assets, net of current portion 8,131 3,874 Intangible assets, net 102,000 95,203 Goodwill 198,253 177,713 Total assets $ 430,963 $ 383,350 Liabilities & Stockholders' Equity Current liabilities Accounts payable $ 7,035 $ 8,079 Current portion of long-term debt 3,141 4,394 Deferred revenue 11,590 11,529 Accrued vacation 6,214 5,262 Other accrued liabilities 16,475 17,163 Total current liabilities 44,455 46,427 Long-term debt, less current portion 136,388 94,966 Operating lease liabilities, net of current portion 5,651 5,505 Deferred tax liabilities 12,758 13,880 Total liabilities 199,252 160,778 Stockholders' Equity Common stock, $0.001 par value; 30,000 shares authorized; 14,913 and 14,734 shares issued 15 15 Treasury stock, 354 and 89 shares (14,500 ) (2,576 ) Additional paid-in capital 192,275 187,079 Retained earnings 53,921 38,054 Total stockholders' equity 231,711 222,572 Total liabilities and stockholders' equity $ 430,963 $ 383,350 Computer Programs and Systems, Inc. Condensed Consolidated Statements of Cash Flows (In '000s) (Unaudited) Twelve Months Ended December 31, 2022 2021 Operating activities: Net income $ 15,867 $ 18,430 Adjustments to net income: Provision for bad debt 992 2,592 Deferred taxes (6,688 ) 3,502 Stock-based compensation 5,173 5,457 Depreciation 2,443 2,156 Loss on extinguishment of debt 125 - Amortization of acquisition-related intangibles 17,403 13,786 Amortization of software development costs 3,484 931 Amortization of deferred finance costs 332 293 Gain on contingent consideration (565 ) - Loss on disposal of PP&E - 313 Changes in operating assets and liabilities: Accounts receivable (12,428 ) (3,204 ) Financing receivables 6,144 8,098 Inventories 71 229 Prepaid expenses and other (2,930 ) (3,914 ) Accounts payable (1,429 ) (615 ) Deferred revenue 61 2,099 Other liabilities 422 401 Prepaid income taxes 3,898 (2,810 ) Net cash provided by operating activities 32,375 47,744 Investing activities: Purchase of business, net of cash received (43,364 ) (59,634 ) Investment in software development (19,097 ) (9,365 ) Purchases of property and equipment (270 ) (920 ) Net cash used in investing activities (62,731 ) (69,919 ) Financing activities: Treasury stock purchases (11,924 ) (1,315 ) Proceeds from long-term debt 575 - Payments of long-term debt principal (3,563 ) (3,750 ) Proceeds from revolving line of credit 48,000 61,000 Payments of revolving line of credit (5,300 ) (35,000 ) Payments of contingent consideration (1,935 ) - Proceeds from exercise of stock options 23 - Net cash provided by (used in) financing activities 25,876 20,935 Net decrease in cash and cash equivalents (4,480 ) (1,240 ) Cash and cash equivalents, beginning of period 11,431 12,671 Cash and cash equivalents, end of period $ 6,951 $ 11,431 Computer Programs and Systems, Inc. Consolidated Bookings (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 TruBridge(1) $ 13,373 $ 5,084 $ 48,065 $ 20,333 EHR(2) 10,678 8,232 38,152 40,873 Patient Engagement(3) 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) Generally calculated as the total contract price (for non-recurring, project-related amounts) and annualized contract value (for recurring amounts) (2) Generally calculated as the total contract price (for system sales) and annualized contract value (for support). (3) Generally calculated as the total contract value. Computer Programs and Systems, Inc. Bookings Composition (In '000s, except per share data) (Unaudited) Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle Net new(1) $ 5,173 $ 681 $ 14,830 $ 6,959 Cross-sell(1) 8,090 4,079 29,962 12,477 TruCode 110 324 3,273 897 Electronic health record Non-subscription sales(2) 4,181 2,436 16,870 12,581 Subscription revenue(3) 5,191 4,439 16,698 23,468 Other 1,306 1,357 4,584 4,824 Patient Engagement 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) “Net new” represents bookings from outside the Company’s core EHR client base, and “Cross-sell” represents bookings from existing EHR customers. In each case, generally comprised of recurring revenues to be recognized ratably over a one-year period and an average timeframe for commencement of bookings-to-revenue conversion of four to six months following contract execution. (2) Represents nonrecurring revenues that generally exhibit a timeframe for bookings-to-revenue conversion of five to six months following contract execution. (3) Represents recurring revenues to be recognized on a monthly basis over a weighted-average contract period of five years, with a start date in the next 12 months and an average timeframe for commencement of bookings-to-revenue conversion of five to six months following contract execution. Computer Programs and Systems, Inc. Acute Care EHR Net New License Mix Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 SaaS(1) 3 2 19 10 Perpetual license(2) - - - 7 Total 3 2 19 17 (1) Exhibits revenue attribution that is recurring in nature. (2) Exhibits revenue attribution that is nonrecurring in nature. Computer Programs and Systems, Inc. Electronic Health Record Revenue Composition (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Recurring revenues - electronic health record Acute Care EHR $ 28,007 $ 27,648 $ 109,340 $ 108,440 Post-acute Care EHR 3,879 4,070 15,384 16,472 Total recurring revenues - system sales and support 31,886 31,718 124,724 124,912 Nonrecurring revenues - electronic health record Acute Care EHR 3,672 3,154 13,138 16,939 Post-acute Care EHR 410 345 1,961 1,258 Total nonrecurring revenues - system sales and support 4,082 3,499 15,099 18,197 Total system sales and support revenues $ 35,968 $ 35,217 $ 139,823 $ 143,109 Computer Programs and Systems, Inc. Client Net Patient Revenue ("NPR") (In millions) (Unaudited) As of: 12/31/2019 12/31/2020 12/31/2021 3/31/2022 6/30/2022 9/30/2022 12/31/2022 Client NPR(1) $ 1,844 $ 2,146 $ 2,190 $ 2,880 $ 2,946 $ 2,958 $ 2,991 (1) Client NPR defined as the aggregate annual net patient revenue for hospital customers contracted for our full-service revenue cycle outsourcing solution. Computer Programs and Systems, Inc. Adjusted EBITDA - by Segment (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle $ 9,306 $ 8,049 $ 36,242 $ 30,211 Electronic health record 4,030 4,925 19,091 23,061 Patient engagement (108 ) 1,350 566 (595 ) Total $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Adjusted EBITDA: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Deferred revenue and other acquisition-related adjustments - 201 109 747 Depreciation expense 553 515 2,443 2,156 Amortization of software development costs 1,200 404 3,483 931 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Interest expense and other, net 2,012 543 5,267 1,632 Gain on contingent consideration 427 - (565 ) - Provision for income taxes (690 ) 1,581 2,214 4,646 Adjusted EBITDA $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Non-GAAP Net Income and Non-GAAP EPS: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Pre-tax adjustments for Non-GAAP EPS: Deferred revenue and other acquisition-related adjustments - 201 109 747 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Non-operating loss from lease termination (non-cash) - - - 313 Non-cash interest expense 90 73 332 293 Loss on extinguishment of debt - - 125 - After-tax adjustments for Non-GAAP EPS: Tax-effect of pre-tax adjustments, at 21% (1,533 ) (1,250 ) (5,806 ) (5,352 ) Tax shortfall (windfall) from stock-based compensation - - (112 ) (84 ) Gain on contingent consideration 427 - (565 ) - Non-GAAP net income $ 8,710 $ 10,104 $ 37,031 $ 38,482 Weighted average shares outstanding, diluted 14,210 14,362 14,356 14,318 Non-GAAP EPS $ 0.61 $ 0.70 $ 2.58 $ 2.69 Explanation of Non-GAAP Financial Measures We report our financial results in accordance with accounting principles generally accepted in the United States of America, or “GAAP.” However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures that are prepared in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management uses these non-GAAP financial measures in order to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. In addition, management understands that some investors and financial analysts find these non-GAAP financial measures helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. As such, to supplement the GAAP information provided, we present in this press release and during the live webcast discussing our financial results the following non‑GAAP financial measures: Adjusted EBITDA, Non-GAAP net income, and Non-GAAP earnings per share (“EPS”). We calculate each of these non-GAAP financial measures as follows: Adjusted EBITDA – Adjusted EBITDA consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) depreciation expense; (iii) amortization of software development costs; (iv) amortization of acquisition-related intangible assets; (v) stock-based compensation; (vi) severance and other non‑recurring charges; (vii) interest expense and other, net; (viii) gain on contingent consideration; and (ix) the provision for income taxes. Non-GAAP net income – Non-GAAP net income consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) amortization of acquisition-related intangible assets; (iii) stock-based compensation; (iv) severance and other non-recurring charges; (v) non-operating loss from lease termination (non-cash); (vi) non-cash interest expense; (vii) loss on extinguishment of debt and (viii) the total tax effect of items (i) through (vii). Adjustments to Non-GAAP net income also include the after-tax effect of the shortfall (windfall) from stock-based compensation and gain on contingent consideration. Non-GAAP EPS – Non-GAAP EPS consists of Non-GAAP net income, as defined above, divided by weighted average shares outstanding (diluted) in the applicable period. Certain of the items excluded or adjusted to arrive at these non-GAAP financial measures are described below: Deferred revenue purchase accounting adjustments – Deferred revenue purchase accounting adjustments includes acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in business acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree’s software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. We add back deferred revenue and other adjustments for non-GAAP financial measures because we believe the inclusion of this amount directly correlates to the underlying performance of our operations. Amortization of acquisition-related intangible assets – Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. We exclude acquisition-related amortization expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods. Stock-based compensation – Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. We exclude stock-based compensation expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods. Severance and other non-recurring charges – Non-recurring charges relate to certain severance and other charges incurred in connection with activities that are considered one-time. We exclude non-recurring expenses (primarily related to costs associated with our recent business transformation initiative and one-time lease terminations costs) and transaction-related costs from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-operating loss from lease termination (non-cash) – Non-operating loss from lease termination relates solely to the write-off of the remaining net book value of leasehold improvements and other property and equipment associated with operating leases terminated as a result of specific actions taken during the period. We exclude such non-operating lease termination losses from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-cash interest expense – Non-cash interest expense includes amortization of deferred debt issuance costs. We exclude non-cash interest expense from non-GAAP financial measures because we believe these non-cash amounts relate to specific transactions and, as such, may not directly correlate to the underlying performance of our business operations. Tax shortfall (windfall) from stock-based compensation – ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, became effective for the Company during the third quarter of 2017 and changes the treatment of tax shortfall and excess tax benefits arising from stock‑based compensation arrangements. Prior to ASU 2016-09, these amounts were recorded as an increase (for excess benefits) or decrease (for shortfalls) to additional paid-in capital. With the adoption of ASU 2016-09, these amounts are now captured in the period’s income tax expense. We exclude this component of income tax expense from non-GAAP financial measures because we believe (i) the amount of such expenses or benefits in any specific period may not directly correlate to the underlying performance of our business operations; and (ii) such expenses or benefits can vary significantly between periods as a result of the valuation of grants of new stock-based awards, the timing of vesting of awards, and periodic movements in the fair value of our common stock. Gain on contingent consideration – The purchase agreement for our acquisition of TruCode in 2021 contained contingent consideration, or “earnout,” provisions whereby the previous shareholders of TruCode would receive additional consideration at the conclusion of a one-year period beginning on the acquisition date and ending on the first anniversary of the acquisition date, depending on the achievement of certain profitability targets. After the initial measurement period, U.S. GAAP requires that any adjustments to the estimated fair value of this contingent liability, including upon final determination of amounts due, should be recorded in the relevant period’s earnings. We exclude gains on contingent consideration from non-GAAP financial measures because we believe (i) the amount of such gains in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such gains can vary significantly between periods. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance. In addition, management may use Adjusted EBITDA, Non-GAAP net income and/or Non-GAAP EPS to measure the achievement of performance objectives under the Company’s stock and cash incentive programs. Note, however, that these non-GAAP financial measures are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures presented by other companies, limiting their usefulness as comparative measures. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Additionally, there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of the non-GAAP financial measures presented in this press release. Investors and potential investors are encouraged to review the “Unaudited Reconciliation of Non‑GAAP Financial Measures” above. View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005792/en/Contacts Tracey Schroeder Chief Marketing Officer Tracey.schroeder@cpsi.com (251) 639-8100 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
CPSI Announces Fourth Quarter and Full Year 2022 Results By: CPSI via Business Wire February 14, 2023 at 16:05 PM EST CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced results for the fourth quarter and year ended December 31, 2022. Highlights include: Fourth quarter 2022 TruBridge revenue cycle management (RCM) revenue grew by 29% compared to fourth quarter 2021, now representing 98% recurring revenue and 55% of CPSI’s total revenue Continued success in both winning new clients and cross-selling RCM solution Full year 2023 revenue guidance between $340 million and $350 million “2022 was an important building year for CPSI as we worked to leverage the well-established organization to drive innovation and growth for the years ahead,” said Chris Fowler, chief executive officer of CPSI. “Our full year results were driven in large part by the success of our TruBridge RCM business as we converted existing customers and focused on adding new, small- and mid-sized hospitals looking to simplify their revenue cycle needs. We also focused on strengthening our customer relationships, which translated to continued stability in our retention rate of over 95%. During the second half of the year, we expanded our leadership team, deepening our expertise and ensuring we are best positioned to execute and seize the growth opportunities ahead of us.” Fourth Quarter 2022 All comparisons are to the quarter ended December 31, 2021, unless otherwise noted. Bookings of $24.7 million compared to $15.6 million Revenue of $83.2 million compared to $74.0 million TruBridge RCM revenue of $45.7 million represented 55% of CPSI’s total revenue, an increase of 29% GAAP net income of $2.5 million and non-GAAP net income of $8.7 million GAAP earnings per diluted share of $0.17 and non-GAAP earnings per diluted share of $0.61 Adjusted EBITDA of $13.2 million compared to $14.3 million Full Year 2022 All comparisons are to the year ended December 31, 2021, unless otherwise noted. Bookings of $89.4 million compared to $70.2 million Revenue of $326.6 million compared to $280.6 million TruBridge RCM revenue of $179.9 million represented 55% of CPSI’s total revenue, an increase of 37% GAAP net income of $15.9 million and non-GAAP net income of $37.0 million GAAP earnings per diluted share of $1.08 and non-GAAP earnings per diluted share of $2.58 Adjusted EBITDA of $55.9 million compared to $52.7 million Net debt of $132.6 million 2023 Outlook For full year 2023, the Company is providing an initial outlook of: Revenue in the range of $340 million to $350 million GAAP net income in the range of $11 million to $15 million Adjusted EBITDA in the range of $59 million to $63 million Conference Call Information CPSI will hold a live webcast to discuss fourth quarter and full year 2022 results today, Tuesday, February 14, 2023, at 4:30 p.m. Eastern time. A 30-day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company’s website, www.cpsi.com. About CPSI CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and other healthcare systems. Founded in 1979, CPSI is the parent of six companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC, iNetXperts, Corp. d/b/a Get Real Health, TruCode LLC, and Healthcare Resource Group, Inc. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive acute care EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of post-acute care EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting and managed IT services, along with its complete RCM solution, for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. TruCode provides medical coding software that enables complete and accurate code assignment for optimal reimbursement. HRG provides specialized RCM solutions for facilities of all sizes. For more information, visit www.cpsi.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; federal, state and local government actions to address and contain the impact of COVID-19 and their impact on us and our hospital clients; operational disruptions and heightened cybersecurity risks due to a significant percentage of our workforce working remotely; saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential inability to properly manage growth in new markets we may enter; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; potential failure to develop new products or enhance current products that keep pace with market demands; failure to develop new technology and products in response to market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; general economic conditions, including changes in the financial and credit markets that may affect the availability and cost of credit to us or our customers; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; lack of employment or non-competition agreement with most of our key personnel; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K. Relative to our dividend policy, the payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our leverage, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release. Computer Programs and Systems, Inc. Condensed Consolidated Statements of Income (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Sales revenues: Revenue cycle $ 45,670 $ 35,491 $ 179,870 $ 131,242 Electronic health record 35,968 35,217 139,823 143,109 Patient engagement 1,586 3,293 6,955 6,278 Total sales revenues 83,224 74,001 326,648 280,629 Costs of sales: Revenue cycle 25,941 17,907 97,010 66,015 Electronic health record 19,069 18,415 71,347 70,664 Patient engagement 1,062 827 3,856 3,068 Total costs of sales 46,072 37,149 172,213 139,747 Gross profit 37,152 36,852 154,435 140,882 Operating expenses: Product development 8,890 7,791 30,926 30,389 Sales and marketing 4,552 6,164 27,131 21,978 General and administrative 14,958 11,700 56,192 50,022 Amortization of acquisition-related intangibles 4,486 3,672 17,403 13,786 Total operating expenses 32,886 29,327 131,652 116,175 Operating income 4,266 7,525 22,783 24,707 Other income (expense): Other income 264 368 1,178 1,529 (Loss) gain on contingent consideration (427 ) - 565 - Loss on extinguishment of debt - - (125 ) - Interest expense (2,276 ) (911 ) (6,320 ) (3,160 ) Total other income (expense) (2,439 ) (543 ) (4,702 ) (1,631 ) Income before taxes 1,827 6,982 18,081 23,076 Provision for income taxes (690 ) 1,581 2,214 4,646 Net income $ 2,517 $ 5,401 $ 15,867 $ 18,430 Net income per common share—basic $ 0.17 $ 0.37 $ 1.08 $ 1.26 Net income per common share—diluted $ 0.17 $ 0.37 $ 1.08 $ 1.26 Weighted average shares outstanding used in per common share computations: Basic 14,210 14,332 14,356 14,290 Diluted 14,210 14,362 14,356 14,318 Computer Programs and Systems, Inc. Condensed Consolidated Balance Sheets (In '000s, except per share data) December 31, 2022 (unaudited) December 31, 2021 (unaudited) Assets Current assets Cash and cash equivalents $ 6,951 $ 11,431 Accounts receivable, net of allowance for doubtful accounts of $2,854 and $1,826, respectively 51,311 34,431 Financing receivables, current portion, net 4,474 6,488 Inventories 784 855 Prepaid income taxes 701 4,599 Prepaid expenses and other 10,338 11,194 Total current assets 74,559 68,998 Property & equipment, net 9,884 11,590 Software development costs, net 27,257 11,644 Operating lease assets 7,567 7,097 Financing receivables, net of current portion 3,312 7,231 Other assets, net of current portion 8,131 3,874 Intangible assets, net 102,000 95,203 Goodwill 198,253 177,713 Total assets $ 430,963 $ 383,350 Liabilities & Stockholders' Equity Current liabilities Accounts payable $ 7,035 $ 8,079 Current portion of long-term debt 3,141 4,394 Deferred revenue 11,590 11,529 Accrued vacation 6,214 5,262 Other accrued liabilities 16,475 17,163 Total current liabilities 44,455 46,427 Long-term debt, less current portion 136,388 94,966 Operating lease liabilities, net of current portion 5,651 5,505 Deferred tax liabilities 12,758 13,880 Total liabilities 199,252 160,778 Stockholders' Equity Common stock, $0.001 par value; 30,000 shares authorized; 14,913 and 14,734 shares issued 15 15 Treasury stock, 354 and 89 shares (14,500 ) (2,576 ) Additional paid-in capital 192,275 187,079 Retained earnings 53,921 38,054 Total stockholders' equity 231,711 222,572 Total liabilities and stockholders' equity $ 430,963 $ 383,350 Computer Programs and Systems, Inc. Condensed Consolidated Statements of Cash Flows (In '000s) (Unaudited) Twelve Months Ended December 31, 2022 2021 Operating activities: Net income $ 15,867 $ 18,430 Adjustments to net income: Provision for bad debt 992 2,592 Deferred taxes (6,688 ) 3,502 Stock-based compensation 5,173 5,457 Depreciation 2,443 2,156 Loss on extinguishment of debt 125 - Amortization of acquisition-related intangibles 17,403 13,786 Amortization of software development costs 3,484 931 Amortization of deferred finance costs 332 293 Gain on contingent consideration (565 ) - Loss on disposal of PP&E - 313 Changes in operating assets and liabilities: Accounts receivable (12,428 ) (3,204 ) Financing receivables 6,144 8,098 Inventories 71 229 Prepaid expenses and other (2,930 ) (3,914 ) Accounts payable (1,429 ) (615 ) Deferred revenue 61 2,099 Other liabilities 422 401 Prepaid income taxes 3,898 (2,810 ) Net cash provided by operating activities 32,375 47,744 Investing activities: Purchase of business, net of cash received (43,364 ) (59,634 ) Investment in software development (19,097 ) (9,365 ) Purchases of property and equipment (270 ) (920 ) Net cash used in investing activities (62,731 ) (69,919 ) Financing activities: Treasury stock purchases (11,924 ) (1,315 ) Proceeds from long-term debt 575 - Payments of long-term debt principal (3,563 ) (3,750 ) Proceeds from revolving line of credit 48,000 61,000 Payments of revolving line of credit (5,300 ) (35,000 ) Payments of contingent consideration (1,935 ) - Proceeds from exercise of stock options 23 - Net cash provided by (used in) financing activities 25,876 20,935 Net decrease in cash and cash equivalents (4,480 ) (1,240 ) Cash and cash equivalents, beginning of period 11,431 12,671 Cash and cash equivalents, end of period $ 6,951 $ 11,431 Computer Programs and Systems, Inc. Consolidated Bookings (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 TruBridge(1) $ 13,373 $ 5,084 $ 48,065 $ 20,333 EHR(2) 10,678 8,232 38,152 40,873 Patient Engagement(3) 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) Generally calculated as the total contract price (for non-recurring, project-related amounts) and annualized contract value (for recurring amounts) (2) Generally calculated as the total contract price (for system sales) and annualized contract value (for support). (3) Generally calculated as the total contract value. Computer Programs and Systems, Inc. Bookings Composition (In '000s, except per share data) (Unaudited) Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle Net new(1) $ 5,173 $ 681 $ 14,830 $ 6,959 Cross-sell(1) 8,090 4,079 29,962 12,477 TruCode 110 324 3,273 897 Electronic health record Non-subscription sales(2) 4,181 2,436 16,870 12,581 Subscription revenue(3) 5,191 4,439 16,698 23,468 Other 1,306 1,357 4,584 4,824 Patient Engagement 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) “Net new” represents bookings from outside the Company’s core EHR client base, and “Cross-sell” represents bookings from existing EHR customers. In each case, generally comprised of recurring revenues to be recognized ratably over a one-year period and an average timeframe for commencement of bookings-to-revenue conversion of four to six months following contract execution. (2) Represents nonrecurring revenues that generally exhibit a timeframe for bookings-to-revenue conversion of five to six months following contract execution. (3) Represents recurring revenues to be recognized on a monthly basis over a weighted-average contract period of five years, with a start date in the next 12 months and an average timeframe for commencement of bookings-to-revenue conversion of five to six months following contract execution. Computer Programs and Systems, Inc. Acute Care EHR Net New License Mix Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 SaaS(1) 3 2 19 10 Perpetual license(2) - - - 7 Total 3 2 19 17 (1) Exhibits revenue attribution that is recurring in nature. (2) Exhibits revenue attribution that is nonrecurring in nature. Computer Programs and Systems, Inc. Electronic Health Record Revenue Composition (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Recurring revenues - electronic health record Acute Care EHR $ 28,007 $ 27,648 $ 109,340 $ 108,440 Post-acute Care EHR 3,879 4,070 15,384 16,472 Total recurring revenues - system sales and support 31,886 31,718 124,724 124,912 Nonrecurring revenues - electronic health record Acute Care EHR 3,672 3,154 13,138 16,939 Post-acute Care EHR 410 345 1,961 1,258 Total nonrecurring revenues - system sales and support 4,082 3,499 15,099 18,197 Total system sales and support revenues $ 35,968 $ 35,217 $ 139,823 $ 143,109 Computer Programs and Systems, Inc. Client Net Patient Revenue ("NPR") (In millions) (Unaudited) As of: 12/31/2019 12/31/2020 12/31/2021 3/31/2022 6/30/2022 9/30/2022 12/31/2022 Client NPR(1) $ 1,844 $ 2,146 $ 2,190 $ 2,880 $ 2,946 $ 2,958 $ 2,991 (1) Client NPR defined as the aggregate annual net patient revenue for hospital customers contracted for our full-service revenue cycle outsourcing solution. Computer Programs and Systems, Inc. Adjusted EBITDA - by Segment (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle $ 9,306 $ 8,049 $ 36,242 $ 30,211 Electronic health record 4,030 4,925 19,091 23,061 Patient engagement (108 ) 1,350 566 (595 ) Total $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Adjusted EBITDA: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Deferred revenue and other acquisition-related adjustments - 201 109 747 Depreciation expense 553 515 2,443 2,156 Amortization of software development costs 1,200 404 3,483 931 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Interest expense and other, net 2,012 543 5,267 1,632 Gain on contingent consideration 427 - (565 ) - Provision for income taxes (690 ) 1,581 2,214 4,646 Adjusted EBITDA $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Non-GAAP Net Income and Non-GAAP EPS: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Pre-tax adjustments for Non-GAAP EPS: Deferred revenue and other acquisition-related adjustments - 201 109 747 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Non-operating loss from lease termination (non-cash) - - - 313 Non-cash interest expense 90 73 332 293 Loss on extinguishment of debt - - 125 - After-tax adjustments for Non-GAAP EPS: Tax-effect of pre-tax adjustments, at 21% (1,533 ) (1,250 ) (5,806 ) (5,352 ) Tax shortfall (windfall) from stock-based compensation - - (112 ) (84 ) Gain on contingent consideration 427 - (565 ) - Non-GAAP net income $ 8,710 $ 10,104 $ 37,031 $ 38,482 Weighted average shares outstanding, diluted 14,210 14,362 14,356 14,318 Non-GAAP EPS $ 0.61 $ 0.70 $ 2.58 $ 2.69 Explanation of Non-GAAP Financial Measures We report our financial results in accordance with accounting principles generally accepted in the United States of America, or “GAAP.” However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures that are prepared in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management uses these non-GAAP financial measures in order to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. In addition, management understands that some investors and financial analysts find these non-GAAP financial measures helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. As such, to supplement the GAAP information provided, we present in this press release and during the live webcast discussing our financial results the following non‑GAAP financial measures: Adjusted EBITDA, Non-GAAP net income, and Non-GAAP earnings per share (“EPS”). We calculate each of these non-GAAP financial measures as follows: Adjusted EBITDA – Adjusted EBITDA consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) depreciation expense; (iii) amortization of software development costs; (iv) amortization of acquisition-related intangible assets; (v) stock-based compensation; (vi) severance and other non‑recurring charges; (vii) interest expense and other, net; (viii) gain on contingent consideration; and (ix) the provision for income taxes. Non-GAAP net income – Non-GAAP net income consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) amortization of acquisition-related intangible assets; (iii) stock-based compensation; (iv) severance and other non-recurring charges; (v) non-operating loss from lease termination (non-cash); (vi) non-cash interest expense; (vii) loss on extinguishment of debt and (viii) the total tax effect of items (i) through (vii). Adjustments to Non-GAAP net income also include the after-tax effect of the shortfall (windfall) from stock-based compensation and gain on contingent consideration. Non-GAAP EPS – Non-GAAP EPS consists of Non-GAAP net income, as defined above, divided by weighted average shares outstanding (diluted) in the applicable period. Certain of the items excluded or adjusted to arrive at these non-GAAP financial measures are described below: Deferred revenue purchase accounting adjustments – Deferred revenue purchase accounting adjustments includes acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in business acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree’s software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. We add back deferred revenue and other adjustments for non-GAAP financial measures because we believe the inclusion of this amount directly correlates to the underlying performance of our operations. Amortization of acquisition-related intangible assets – Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. We exclude acquisition-related amortization expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods. Stock-based compensation – Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. We exclude stock-based compensation expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods. Severance and other non-recurring charges – Non-recurring charges relate to certain severance and other charges incurred in connection with activities that are considered one-time. We exclude non-recurring expenses (primarily related to costs associated with our recent business transformation initiative and one-time lease terminations costs) and transaction-related costs from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-operating loss from lease termination (non-cash) – Non-operating loss from lease termination relates solely to the write-off of the remaining net book value of leasehold improvements and other property and equipment associated with operating leases terminated as a result of specific actions taken during the period. We exclude such non-operating lease termination losses from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-cash interest expense – Non-cash interest expense includes amortization of deferred debt issuance costs. We exclude non-cash interest expense from non-GAAP financial measures because we believe these non-cash amounts relate to specific transactions and, as such, may not directly correlate to the underlying performance of our business operations. Tax shortfall (windfall) from stock-based compensation – ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, became effective for the Company during the third quarter of 2017 and changes the treatment of tax shortfall and excess tax benefits arising from stock‑based compensation arrangements. Prior to ASU 2016-09, these amounts were recorded as an increase (for excess benefits) or decrease (for shortfalls) to additional paid-in capital. With the adoption of ASU 2016-09, these amounts are now captured in the period’s income tax expense. We exclude this component of income tax expense from non-GAAP financial measures because we believe (i) the amount of such expenses or benefits in any specific period may not directly correlate to the underlying performance of our business operations; and (ii) such expenses or benefits can vary significantly between periods as a result of the valuation of grants of new stock-based awards, the timing of vesting of awards, and periodic movements in the fair value of our common stock. Gain on contingent consideration – The purchase agreement for our acquisition of TruCode in 2021 contained contingent consideration, or “earnout,” provisions whereby the previous shareholders of TruCode would receive additional consideration at the conclusion of a one-year period beginning on the acquisition date and ending on the first anniversary of the acquisition date, depending on the achievement of certain profitability targets. After the initial measurement period, U.S. GAAP requires that any adjustments to the estimated fair value of this contingent liability, including upon final determination of amounts due, should be recorded in the relevant period’s earnings. We exclude gains on contingent consideration from non-GAAP financial measures because we believe (i) the amount of such gains in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such gains can vary significantly between periods. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance. In addition, management may use Adjusted EBITDA, Non-GAAP net income and/or Non-GAAP EPS to measure the achievement of performance objectives under the Company’s stock and cash incentive programs. Note, however, that these non-GAAP financial measures are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures presented by other companies, limiting their usefulness as comparative measures. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Additionally, there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of the non-GAAP financial measures presented in this press release. Investors and potential investors are encouraged to review the “Unaudited Reconciliation of Non‑GAAP Financial Measures” above. View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005792/en/Contacts Tracey Schroeder Chief Marketing Officer Tracey.schroeder@cpsi.com (251) 639-8100
CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced results for the fourth quarter and year ended December 31, 2022. Highlights include: Fourth quarter 2022 TruBridge revenue cycle management (RCM) revenue grew by 29% compared to fourth quarter 2021, now representing 98% recurring revenue and 55% of CPSI’s total revenue Continued success in both winning new clients and cross-selling RCM solution Full year 2023 revenue guidance between $340 million and $350 million “2022 was an important building year for CPSI as we worked to leverage the well-established organization to drive innovation and growth for the years ahead,” said Chris Fowler, chief executive officer of CPSI. “Our full year results were driven in large part by the success of our TruBridge RCM business as we converted existing customers and focused on adding new, small- and mid-sized hospitals looking to simplify their revenue cycle needs. We also focused on strengthening our customer relationships, which translated to continued stability in our retention rate of over 95%. During the second half of the year, we expanded our leadership team, deepening our expertise and ensuring we are best positioned to execute and seize the growth opportunities ahead of us.” Fourth Quarter 2022 All comparisons are to the quarter ended December 31, 2021, unless otherwise noted. Bookings of $24.7 million compared to $15.6 million Revenue of $83.2 million compared to $74.0 million TruBridge RCM revenue of $45.7 million represented 55% of CPSI’s total revenue, an increase of 29% GAAP net income of $2.5 million and non-GAAP net income of $8.7 million GAAP earnings per diluted share of $0.17 and non-GAAP earnings per diluted share of $0.61 Adjusted EBITDA of $13.2 million compared to $14.3 million Full Year 2022 All comparisons are to the year ended December 31, 2021, unless otherwise noted. Bookings of $89.4 million compared to $70.2 million Revenue of $326.6 million compared to $280.6 million TruBridge RCM revenue of $179.9 million represented 55% of CPSI’s total revenue, an increase of 37% GAAP net income of $15.9 million and non-GAAP net income of $37.0 million GAAP earnings per diluted share of $1.08 and non-GAAP earnings per diluted share of $2.58 Adjusted EBITDA of $55.9 million compared to $52.7 million Net debt of $132.6 million 2023 Outlook For full year 2023, the Company is providing an initial outlook of: Revenue in the range of $340 million to $350 million GAAP net income in the range of $11 million to $15 million Adjusted EBITDA in the range of $59 million to $63 million Conference Call Information CPSI will hold a live webcast to discuss fourth quarter and full year 2022 results today, Tuesday, February 14, 2023, at 4:30 p.m. Eastern time. A 30-day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company’s website, www.cpsi.com. About CPSI CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and other healthcare systems. Founded in 1979, CPSI is the parent of six companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC, iNetXperts, Corp. d/b/a Get Real Health, TruCode LLC, and Healthcare Resource Group, Inc. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive acute care EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of post-acute care EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting and managed IT services, along with its complete RCM solution, for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. TruCode provides medical coding software that enables complete and accurate code assignment for optimal reimbursement. HRG provides specialized RCM solutions for facilities of all sizes. For more information, visit www.cpsi.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; federal, state and local government actions to address and contain the impact of COVID-19 and their impact on us and our hospital clients; operational disruptions and heightened cybersecurity risks due to a significant percentage of our workforce working remotely; saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential inability to properly manage growth in new markets we may enter; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; potential failure to develop new products or enhance current products that keep pace with market demands; failure to develop new technology and products in response to market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; general economic conditions, including changes in the financial and credit markets that may affect the availability and cost of credit to us or our customers; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; lack of employment or non-competition agreement with most of our key personnel; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K. Relative to our dividend policy, the payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our leverage, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release. Computer Programs and Systems, Inc. Condensed Consolidated Statements of Income (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Sales revenues: Revenue cycle $ 45,670 $ 35,491 $ 179,870 $ 131,242 Electronic health record 35,968 35,217 139,823 143,109 Patient engagement 1,586 3,293 6,955 6,278 Total sales revenues 83,224 74,001 326,648 280,629 Costs of sales: Revenue cycle 25,941 17,907 97,010 66,015 Electronic health record 19,069 18,415 71,347 70,664 Patient engagement 1,062 827 3,856 3,068 Total costs of sales 46,072 37,149 172,213 139,747 Gross profit 37,152 36,852 154,435 140,882 Operating expenses: Product development 8,890 7,791 30,926 30,389 Sales and marketing 4,552 6,164 27,131 21,978 General and administrative 14,958 11,700 56,192 50,022 Amortization of acquisition-related intangibles 4,486 3,672 17,403 13,786 Total operating expenses 32,886 29,327 131,652 116,175 Operating income 4,266 7,525 22,783 24,707 Other income (expense): Other income 264 368 1,178 1,529 (Loss) gain on contingent consideration (427 ) - 565 - Loss on extinguishment of debt - - (125 ) - Interest expense (2,276 ) (911 ) (6,320 ) (3,160 ) Total other income (expense) (2,439 ) (543 ) (4,702 ) (1,631 ) Income before taxes 1,827 6,982 18,081 23,076 Provision for income taxes (690 ) 1,581 2,214 4,646 Net income $ 2,517 $ 5,401 $ 15,867 $ 18,430 Net income per common share—basic $ 0.17 $ 0.37 $ 1.08 $ 1.26 Net income per common share—diluted $ 0.17 $ 0.37 $ 1.08 $ 1.26 Weighted average shares outstanding used in per common share computations: Basic 14,210 14,332 14,356 14,290 Diluted 14,210 14,362 14,356 14,318 Computer Programs and Systems, Inc. Condensed Consolidated Balance Sheets (In '000s, except per share data) December 31, 2022 (unaudited) December 31, 2021 (unaudited) Assets Current assets Cash and cash equivalents $ 6,951 $ 11,431 Accounts receivable, net of allowance for doubtful accounts of $2,854 and $1,826, respectively 51,311 34,431 Financing receivables, current portion, net 4,474 6,488 Inventories 784 855 Prepaid income taxes 701 4,599 Prepaid expenses and other 10,338 11,194 Total current assets 74,559 68,998 Property & equipment, net 9,884 11,590 Software development costs, net 27,257 11,644 Operating lease assets 7,567 7,097 Financing receivables, net of current portion 3,312 7,231 Other assets, net of current portion 8,131 3,874 Intangible assets, net 102,000 95,203 Goodwill 198,253 177,713 Total assets $ 430,963 $ 383,350 Liabilities & Stockholders' Equity Current liabilities Accounts payable $ 7,035 $ 8,079 Current portion of long-term debt 3,141 4,394 Deferred revenue 11,590 11,529 Accrued vacation 6,214 5,262 Other accrued liabilities 16,475 17,163 Total current liabilities 44,455 46,427 Long-term debt, less current portion 136,388 94,966 Operating lease liabilities, net of current portion 5,651 5,505 Deferred tax liabilities 12,758 13,880 Total liabilities 199,252 160,778 Stockholders' Equity Common stock, $0.001 par value; 30,000 shares authorized; 14,913 and 14,734 shares issued 15 15 Treasury stock, 354 and 89 shares (14,500 ) (2,576 ) Additional paid-in capital 192,275 187,079 Retained earnings 53,921 38,054 Total stockholders' equity 231,711 222,572 Total liabilities and stockholders' equity $ 430,963 $ 383,350 Computer Programs and Systems, Inc. Condensed Consolidated Statements of Cash Flows (In '000s) (Unaudited) Twelve Months Ended December 31, 2022 2021 Operating activities: Net income $ 15,867 $ 18,430 Adjustments to net income: Provision for bad debt 992 2,592 Deferred taxes (6,688 ) 3,502 Stock-based compensation 5,173 5,457 Depreciation 2,443 2,156 Loss on extinguishment of debt 125 - Amortization of acquisition-related intangibles 17,403 13,786 Amortization of software development costs 3,484 931 Amortization of deferred finance costs 332 293 Gain on contingent consideration (565 ) - Loss on disposal of PP&E - 313 Changes in operating assets and liabilities: Accounts receivable (12,428 ) (3,204 ) Financing receivables 6,144 8,098 Inventories 71 229 Prepaid expenses and other (2,930 ) (3,914 ) Accounts payable (1,429 ) (615 ) Deferred revenue 61 2,099 Other liabilities 422 401 Prepaid income taxes 3,898 (2,810 ) Net cash provided by operating activities 32,375 47,744 Investing activities: Purchase of business, net of cash received (43,364 ) (59,634 ) Investment in software development (19,097 ) (9,365 ) Purchases of property and equipment (270 ) (920 ) Net cash used in investing activities (62,731 ) (69,919 ) Financing activities: Treasury stock purchases (11,924 ) (1,315 ) Proceeds from long-term debt 575 - Payments of long-term debt principal (3,563 ) (3,750 ) Proceeds from revolving line of credit 48,000 61,000 Payments of revolving line of credit (5,300 ) (35,000 ) Payments of contingent consideration (1,935 ) - Proceeds from exercise of stock options 23 - Net cash provided by (used in) financing activities 25,876 20,935 Net decrease in cash and cash equivalents (4,480 ) (1,240 ) Cash and cash equivalents, beginning of period 11,431 12,671 Cash and cash equivalents, end of period $ 6,951 $ 11,431 Computer Programs and Systems, Inc. Consolidated Bookings (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 TruBridge(1) $ 13,373 $ 5,084 $ 48,065 $ 20,333 EHR(2) 10,678 8,232 38,152 40,873 Patient Engagement(3) 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) Generally calculated as the total contract price (for non-recurring, project-related amounts) and annualized contract value (for recurring amounts) (2) Generally calculated as the total contract price (for system sales) and annualized contract value (for support). (3) Generally calculated as the total contract value. Computer Programs and Systems, Inc. Bookings Composition (In '000s, except per share data) (Unaudited) Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle Net new(1) $ 5,173 $ 681 $ 14,830 $ 6,959 Cross-sell(1) 8,090 4,079 29,962 12,477 TruCode 110 324 3,273 897 Electronic health record Non-subscription sales(2) 4,181 2,436 16,870 12,581 Subscription revenue(3) 5,191 4,439 16,698 23,468 Other 1,306 1,357 4,584 4,824 Patient Engagement 620 2,247 3,188 9,007 Total $ 24,671 $ 15,563 $ 89,405 $ 70,213 (1) “Net new” represents bookings from outside the Company’s core EHR client base, and “Cross-sell” represents bookings from existing EHR customers. In each case, generally comprised of recurring revenues to be recognized ratably over a one-year period and an average timeframe for commencement of bookings-to-revenue conversion of four to six months following contract execution. (2) Represents nonrecurring revenues that generally exhibit a timeframe for bookings-to-revenue conversion of five to six months following contract execution. (3) Represents recurring revenues to be recognized on a monthly basis over a weighted-average contract period of five years, with a start date in the next 12 months and an average timeframe for commencement of bookings-to-revenue conversion of five to six months following contract execution. Computer Programs and Systems, Inc. Acute Care EHR Net New License Mix Three Months Ended Twelve Months Ended 12/31/2022 12/31/2021 12/31/2022 12/31/2021 SaaS(1) 3 2 19 10 Perpetual license(2) - - - 7 Total 3 2 19 17 (1) Exhibits revenue attribution that is recurring in nature. (2) Exhibits revenue attribution that is nonrecurring in nature. Computer Programs and Systems, Inc. Electronic Health Record Revenue Composition (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Recurring revenues - electronic health record Acute Care EHR $ 28,007 $ 27,648 $ 109,340 $ 108,440 Post-acute Care EHR 3,879 4,070 15,384 16,472 Total recurring revenues - system sales and support 31,886 31,718 124,724 124,912 Nonrecurring revenues - electronic health record Acute Care EHR 3,672 3,154 13,138 16,939 Post-acute Care EHR 410 345 1,961 1,258 Total nonrecurring revenues - system sales and support 4,082 3,499 15,099 18,197 Total system sales and support revenues $ 35,968 $ 35,217 $ 139,823 $ 143,109 Computer Programs and Systems, Inc. Client Net Patient Revenue ("NPR") (In millions) (Unaudited) As of: 12/31/2019 12/31/2020 12/31/2021 3/31/2022 6/30/2022 9/30/2022 12/31/2022 Client NPR(1) $ 1,844 $ 2,146 $ 2,190 $ 2,880 $ 2,946 $ 2,958 $ 2,991 (1) Client NPR defined as the aggregate annual net patient revenue for hospital customers contracted for our full-service revenue cycle outsourcing solution. Computer Programs and Systems, Inc. Adjusted EBITDA - by Segment (In '000s) Three Months Ended Twelve Months Ended In '000s 12/31/2022 12/31/2021 12/31/2022 12/31/2021 Revenue cycle $ 9,306 $ 8,049 $ 36,242 $ 30,211 Electronic health record 4,030 4,925 19,091 23,061 Patient engagement (108 ) 1,350 566 (595 ) Total $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Adjusted EBITDA: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Deferred revenue and other acquisition-related adjustments - 201 109 747 Depreciation expense 553 515 2,443 2,156 Amortization of software development costs 1,200 404 3,483 931 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Interest expense and other, net 2,012 543 5,267 1,632 Gain on contingent consideration 427 - (565 ) - Provision for income taxes (690 ) 1,581 2,214 4,646 Adjusted EBITDA $ 13,228 $ 14,324 $ 55,899 $ 52,677 Computer Programs and Systems, Inc. Reconciliation of Non-GAAP Financial Measures (In '000s, except per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, Non-GAAP Net Income and Non-GAAP EPS: 2022 2021 2022 2021 Net income, as reported $ 2,517 $ 5,401 $ 15,867 $ 18,430 Pre-tax adjustments for Non-GAAP EPS: Deferred revenue and other acquisition-related adjustments - 201 109 747 Amortization of acquisition-related intangible assets 4,486 3,672 17,403 13,786 Stock-based compensation (111 ) 1,279 5,173 5,457 Severance and other nonrecurring charges 2,834 728 4,505 4,892 Non-operating loss from lease termination (non-cash) - - - 313 Non-cash interest expense 90 73 332 293 Loss on extinguishment of debt - - 125 - After-tax adjustments for Non-GAAP EPS: Tax-effect of pre-tax adjustments, at 21% (1,533 ) (1,250 ) (5,806 ) (5,352 ) Tax shortfall (windfall) from stock-based compensation - - (112 ) (84 ) Gain on contingent consideration 427 - (565 ) - Non-GAAP net income $ 8,710 $ 10,104 $ 37,031 $ 38,482 Weighted average shares outstanding, diluted 14,210 14,362 14,356 14,318 Non-GAAP EPS $ 0.61 $ 0.70 $ 2.58 $ 2.69 Explanation of Non-GAAP Financial Measures We report our financial results in accordance with accounting principles generally accepted in the United States of America, or “GAAP.” However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures that are prepared in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management uses these non-GAAP financial measures in order to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. In addition, management understands that some investors and financial analysts find these non-GAAP financial measures helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. As such, to supplement the GAAP information provided, we present in this press release and during the live webcast discussing our financial results the following non‑GAAP financial measures: Adjusted EBITDA, Non-GAAP net income, and Non-GAAP earnings per share (“EPS”). We calculate each of these non-GAAP financial measures as follows: Adjusted EBITDA – Adjusted EBITDA consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) depreciation expense; (iii) amortization of software development costs; (iv) amortization of acquisition-related intangible assets; (v) stock-based compensation; (vi) severance and other non‑recurring charges; (vii) interest expense and other, net; (viii) gain on contingent consideration; and (ix) the provision for income taxes. Non-GAAP net income – Non-GAAP net income consists of GAAP net income as reported and adjusts for (i) deferred revenue purchase accounting adjustments arising from purchase allocation adjustments related to business acquisitions; (ii) amortization of acquisition-related intangible assets; (iii) stock-based compensation; (iv) severance and other non-recurring charges; (v) non-operating loss from lease termination (non-cash); (vi) non-cash interest expense; (vii) loss on extinguishment of debt and (viii) the total tax effect of items (i) through (vii). Adjustments to Non-GAAP net income also include the after-tax effect of the shortfall (windfall) from stock-based compensation and gain on contingent consideration. Non-GAAP EPS – Non-GAAP EPS consists of Non-GAAP net income, as defined above, divided by weighted average shares outstanding (diluted) in the applicable period. Certain of the items excluded or adjusted to arrive at these non-GAAP financial measures are described below: Deferred revenue purchase accounting adjustments – Deferred revenue purchase accounting adjustments includes acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in business acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree’s software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. We add back deferred revenue and other adjustments for non-GAAP financial measures because we believe the inclusion of this amount directly correlates to the underlying performance of our operations. Amortization of acquisition-related intangible assets – Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. We exclude acquisition-related amortization expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods. Stock-based compensation – Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. We exclude stock-based compensation expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods. Severance and other non-recurring charges – Non-recurring charges relate to certain severance and other charges incurred in connection with activities that are considered one-time. We exclude non-recurring expenses (primarily related to costs associated with our recent business transformation initiative and one-time lease terminations costs) and transaction-related costs from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-operating loss from lease termination (non-cash) – Non-operating loss from lease termination relates solely to the write-off of the remaining net book value of leasehold improvements and other property and equipment associated with operating leases terminated as a result of specific actions taken during the period. We exclude such non-operating lease termination losses from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods. Non-cash interest expense – Non-cash interest expense includes amortization of deferred debt issuance costs. We exclude non-cash interest expense from non-GAAP financial measures because we believe these non-cash amounts relate to specific transactions and, as such, may not directly correlate to the underlying performance of our business operations. Tax shortfall (windfall) from stock-based compensation – ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, became effective for the Company during the third quarter of 2017 and changes the treatment of tax shortfall and excess tax benefits arising from stock‑based compensation arrangements. Prior to ASU 2016-09, these amounts were recorded as an increase (for excess benefits) or decrease (for shortfalls) to additional paid-in capital. With the adoption of ASU 2016-09, these amounts are now captured in the period’s income tax expense. We exclude this component of income tax expense from non-GAAP financial measures because we believe (i) the amount of such expenses or benefits in any specific period may not directly correlate to the underlying performance of our business operations; and (ii) such expenses or benefits can vary significantly between periods as a result of the valuation of grants of new stock-based awards, the timing of vesting of awards, and periodic movements in the fair value of our common stock. Gain on contingent consideration – The purchase agreement for our acquisition of TruCode in 2021 contained contingent consideration, or “earnout,” provisions whereby the previous shareholders of TruCode would receive additional consideration at the conclusion of a one-year period beginning on the acquisition date and ending on the first anniversary of the acquisition date, depending on the achievement of certain profitability targets. After the initial measurement period, U.S. GAAP requires that any adjustments to the estimated fair value of this contingent liability, including upon final determination of amounts due, should be recorded in the relevant period’s earnings. We exclude gains on contingent consideration from non-GAAP financial measures because we believe (i) the amount of such gains in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such gains can vary significantly between periods. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance. In addition, management may use Adjusted EBITDA, Non-GAAP net income and/or Non-GAAP EPS to measure the achievement of performance objectives under the Company’s stock and cash incentive programs. Note, however, that these non-GAAP financial measures are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures presented by other companies, limiting their usefulness as comparative measures. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Additionally, there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of the non-GAAP financial measures presented in this press release. Investors and potential investors are encouraged to review the “Unaudited Reconciliation of Non‑GAAP Financial Measures” above. View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005792/en/